Drug induced autoimmune hepatitis and TNF-α blocking agents: Is there a real relationship?

Autoimmunity Reviews

Volumn 12, Issue 3, 2013, Pages 337-339

  Efe, Cumali ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Adalimumab; Autoimmune hepatitis; Drug induced autoimmune hepatitis; Drug induced liver injury; Etanercept; Infliximab

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; INFLIXIMAB; LIVER ENZYME; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AUTOIMMUNE HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER INJURY; LIVER TOXICITY; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872406488     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.03.010     Document Type: Review

References (28)

1. Atzeni F., Antivalle M., Pallavicini F.B., Caporali R., Bazzani C., Gorla R., et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 2009, 8:431-437.
2. Favalli E.G., Desiati F., Atzeni F., Sarzi-Puttini P., Caporali R., Pallavicini F.B., et al. Serious infections during anti-TNFα treatment in rheumatoid arthritis patients. Autoimmun Rev 2009, 8:266-273.
3. Rosenblum H., Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011, 10:563-568.
4. Sarzi-Puttini P., Atzeni F., Shoenfeld Y., Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005, 4:153-161.
5. Efe C., Ozaslan E., Nasiroglu N., Tunca H., Purnak T., Altiparmak E. The development of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome during the course of connective tissue diseases:report of three cases and review of the literature. Dig Dis Sci 2010, 55:2417-2421.
6. Ramos-Casals M., Ayala M.M., Brito-Zerón P., Callejas J.L., Caminal-Montero L., Camps M.T., et al. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193.
7. Harada K., Akai Y., Koyama S., Ikenaka Y., Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol 2008, 27:1063-1066.
8. Doyle A., Forbes G., Kontorinis N. Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report. J Crohns Colitis 2011, 5:253-255.
9. Goujon C., Dahel K., Bérard F., Guillot I., Gunera-Saad N., Nicolas J.F. Autoimmune hepatitis in two psoriasis patients treated with inflixmab. J Am Acad Dermatol 2010, 63:e43-e44.
10. Tobon G.J., Cañas C., Jaller J.J., Restrepo J.C., Anaya J.M. Serious liver disease induced by infliximab. Clin Rheumatol 2007, 26:578-581.
11. Efe C., Purnak T., Ozaslan E., Wahlin S. Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor α agents. Hepatology 2010, 52:2246-2247.
12. De Rycke L., Baeten D., Kruithof E., Van den Bosch F., Veys E.M., De Keyser F. Infliximab, but not etanercept, induces IgM anti-doublestranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005, 52:2192-2201.
13. Yazdani-Biuki B., Stadlmaier E., Mulabecirovic A., Brezinschek R., Tilz G., Demel U. Blockade of tumour necrosis factor a significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:1224-1226.
14. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
15. Hennes E.M., Zeniya M., Czaja A.J., Parés A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
16. Suzuki A., Brunt E.M., Kleiner D.E., Miquel R., Smyrk T.C., Andrade R.J., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis vs. drug-induced liver injury. Hepatology 2011, 54:931-939.
17. Weiler-Normann C., Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol 2011, 55:747-749.
18. Czaja A.J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011, 56:958-976.
19. Bjornsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040-2048.
20. Shoenfeld Y., Blank M., Abu-Shakra M., Amital H., Barzilai O., Berkun Y., et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases-2008. Isr Med Assoc J 2008, 10:13-19.
21. Gershwin M.E. The mosaic of autoimmunity. Autoimmun Rev 2008, 7:161-163.
22. Czaja A.J. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol 2011, 25:689-700.
23. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 2006, 354:54-66.
24. Quintin E., Scoazec J.Y., Marotte H., Miossec P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther 2010, 12:143.
25. Cravo M., Silva R., Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab. BioDrugs 2010, 14(24 Suppl. 1):25-27.
26. Carlsen K.M., Riis L., Madsen O.R. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009, 28:1001-1003.
27. Adar T., Mizrahi M., Pappo O., Scheiman-Elazary A., Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010, 44:e20-e22.
28. Fathalla B.M., Goldsmith D.P., Pascasio J.M., Baldridge A. Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept. J Clin Rheumatol 2008, 14:297-298.